The Board of Directors of Translate Bio, Inc. appointed Brendan Smith to serve as the company’s corporate strategy and principal financial officer, effective as of Mr. Smith’s first date of employment with the company, which commenced on April 19, 2021. Effective as of the commencement of employment of Mr. Smith, Ronald C. Renaud, Jr., the company’s current chief executive officer, principal executive officer and principal financial officer, will no longer serve as the company’s principal financial officer. Mr. Renaud will continue to serve as the company’s chief executive officer and principal executive officer and as a member of the board. Mr. Smith, age 45, previously held various roles at Boston Consulting Group, or BCG, a management consulting firm, serving most recently as a partner and associate director from July 2018 to March 2021, and as principal healthcare expert from September 2016 to June 2018. At BCG, Mr. Smith led integrated biopharmaceutical client engagements that included planning and executing on research and development strategy, operations, business development and deal diligence. Mr. Smith served as vice president, head of business operations for worldwide research and development at Pfizer Inc., or Pfizer, a pharmaceutical company, from September 2014 to September 2016 and as executive director, head of business strategy and operations at Pfizer from November 2012 to September 2014, where he led financial and headcount planning across discovery and development operations.